Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$63.22 USD

63.22
151,890

-0.28 (-0.44%)

Updated Jul 15, 2024 04:00 PM ET

After-Market: $63.23 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nalak Das headshot

5 Stocks With Recent Price Strength to Enhance Your Returns

by Nalak Das

Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $68.88, marking a -0.17% move from the previous day.

Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA

by Zacks Equity Research

Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.

QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

by Zacks Equity Research

QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.

Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ANIP) Outperforming Other Medical Stocks This Year?

3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)

by Zacks Equity Research

ANI (ANIP) could produce exceptional returns because of its solid growth attributes.

ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $69.44, marking a +1.71% move from the previous day.

Moumita Chattopadhyay headshot

5 Stocks With Increasing Cash Flows to Scoop Up Big Gains

by Moumita Chattopadhyay

Cash gives a company vitality and strength. It holds the key to its existence, development and success, and can indeed be referred to as its lifeblood.

Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest

by Zacks Equity Research

Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest

BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M

by Zacks Equity Research

BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.

Tap These 6 Stocks That Flaunt Sizeable Net Profit Margin

by Zacks Equity Research

Here are six stocks with spectacular net profit margins that investors can bank on for stellar returns.

PhaseBio Stock Up on Breakthrough Therapy Status for PB2452

by Zacks Equity Research

FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

Coherus (CHRS) Catches Eye: Stock Jumps 6.9%

by Zacks Equity Research

Coherus (CHRS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Seattle Genetics (SGEN) Surges: Stock Moves 7.6% Higher

by Zacks Equity Research

Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $70.39, marking a -0.13% move from the previous day.

Palatin Technologies (PTN) in Focus: Stock Moves 5.7% Higher

by Zacks Equity Research

Palatin Technologies (PTN) shares rose nearly 6% in the last trading session, amid huge volumes.

The Zacks Analyst Blog Highlights: ANI Pharmaceuticals, Avianca, Avid, Terex and Encore Wire

by Zacks Equity Research

The Zacks Analyst Blog Highlights: ANI Pharmaceuticals, Avianca, Avid, Terex and Encore Wire

Tirthankar Chakraborty headshot

Fears of Far-Reaching Economic Slowdown Diminish: 5 Picks

by Tirthankar Chakraborty

Encouraging service sector figures from Europe and China, along with increasing optimism in U.S.-China trade negotiations ease fears of a global economic downturn.

Nalak Das headshot

5 Stocks With Recent Price Strength Despite Market Volatility

by Nalak Das

Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink

by Zacks Equity Research

The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink

Moving Average Crossover Alert: ANI Pharmaceuticals

by Zacks Equity Research

ANI Pharmaceuticals, Inc. (ANIP) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

4 Small Biotech Stocks Likely to Witness More Upside in 2019

by Zacks Equity Research

The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for March 29th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

All You Need to Know About ANI (ANIP) Rating Upgrade to Strong Buy

by Zacks Equity Research

ANI (ANIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)

by Zacks Equity Research

ANI (ANIP) possesses solid growth attributes, which could help it handily outperform the market.